Internal and Emergency Medicine

, Volume 7, Issue 1, pp 9–13 | Cite as

Identifying high-risk individuals for cardiovascular disease: similarities between venous and arterial thrombosis in perspective. A 2011 update

  • Matteo Nicola Dario  Di Minno
  • Antonella Tufano
  • Walter Ageno
  • Paolo Prandoni
  • Giovanni Di Minno


The aim of this narrative review is to assess the potential association between arterial and venous thrombotic events. Several studies have suggested that the major cardiovascular risk factors, alone or in combination (e.g. in the metabolic syndrome), are significantly associated with venous thromboembolism (VTE). Recent evidence also suggests that microalbuminuria and non-alcoholic liver steatosis, both markers of arterial disease, may independently predict the risk for VTE. An association between a history of VTE and the risk of future arterial events is also well documented, inflammation and endothelial dysfunction being thought as the common soil on which further investigation in the area should be pursued. The existence of a common pathophysiologic background is also suggested by the evidence that aspirin, low-molecular weight heparin (LMWH) and warfarin are recommended for the prevention and treatment of both venous and arterial thrombosis. In addition, rosuvastatin recently has been shown to prevent venous thromboembolism (VTE) in a time-dependent fashion. Together, these data argue for patients with a history of VTE as being at intermediate/high cardiovascular risk, a concept that implies that VTE patients should undergo a careful assessment for the presence of cardiovascular risk factors and adequate lifestyle changes. The value of routine screening for asymptomatic atherosclerosis (e.g. 2D echocardiography, microalbuminuria, arterial vessel ultrasonography) in these patients should be confirmed in future studies.


Atherosclerosis Arterial thrombosis Venous thrombosis High-risk individuals for cardiovascular disease 


  1. 1.
    Prandoni P, Lensing AWA, Cogo A et al (1996) The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 125:1–7PubMedGoogle Scholar
  2. 2.
    Prandoni P, Villalta S, Bagatella P et al (1997) The clinical course of deep-vein thrombosis. Prospective long-term follow-up of 528 symptomatic patients. Haematologica 82:423–428PubMedGoogle Scholar
  3. 3.
    Prandoni P et al (2003) An association between atherosclerosis and venous thrombosis. NEJM 348:1435–1441PubMedCrossRefGoogle Scholar
  4. 4.
    Ageno W, Dentali F (2008) Venous thromboembolism and arterial thromboembolism. Many similarities, far beyond thrombosis per se. Thromb Haemost 100:181–183PubMedGoogle Scholar
  5. 5.
    Wysokinski WE, Owen WG, Fass DN, Patrzalek DD, Murphy L, McBane RD 2nd (2004) Atrial fibrillation and thrombosis: immunohistochemical differences between in situ and embolized thrombi. J Thromb Haemost 2(9):1637–1644PubMedCrossRefGoogle Scholar
  6. 6.
    Yamashita A, Sumi T, Goto S, Hoshiba Y, Nishihira K, Kawamoto R, Hatakeyama K, Date H, Imamura T, Ogawa H, Asada Y (2006) Detection of von Willebrand factor and tissue factor in platelets-fibrin rich coronary thrombi in acute myocardial infarction. Am J Cardiol 97(1):26–28PubMedCrossRefGoogle Scholar
  7. 7.
    Lacut K, van der Maaten J, Le Gal G, Cornily G, Mottier D, Oger E (2008) Antiplatelet drugs and risk of venous thromboembolism: results from the EDITH case-control study. Haematologica 93(7):1117–1118PubMedCrossRefGoogle Scholar
  8. 8.
    Di Capua M, Di Minno MND, Guida A, Loffredo M, Cuccaro C, Coppola A et al (2010) Coronary artery disease, cerebral non-fatal ischemic stroke in retinal vein occlusion: a 8-years follow-up. NMCD (in press)Google Scholar
  9. 9.
    Hong C, Zhu F, Du D et al (2005) Coronary artery calcification and risk factors for atherosclerosis in patients with venous thromboembolism. Atherosclerosis 183:169–174PubMedCrossRefGoogle Scholar
  10. 10.
    Eliasson A, Bergqvist D, Bjork M, Acosta S, Ogren M, Sternby NH (2006) Incidence and risk of venous thromboembolism in patients with verified arterial thrombosis: a population study based on 23, 796 consecutive autopsies. Thromb Haemost 4:1897–1902CrossRefGoogle Scholar
  11. 11.
    Bhargava S, Parakh R, Manocha A, Ali A, Srivastava LM (2007) Prevalence of hyperhomocysteinemia in vascular disease: comparative study of thrombotic venous disease vis-à-vis occlusive arterial disease. Vascular 15(3):149–153PubMedCrossRefGoogle Scholar
  12. 12.
    Giannakopoulos B, Passam F, Ioannou Y, Krilis SA (2008) How we diagnose the antiphospholipid syndrome. Blood 5:985–994CrossRefGoogle Scholar
  13. 13.
    Landolfi R, Di Gennaro L, Falanga A (2008) Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation. Leukemia 22(11):2020–2028PubMedCrossRefGoogle Scholar
  14. 14.
    Lechner D, Weltermann A (2009) Pathophysiology of chemotherapy-associated thrombosis. Hamostaseologie 29(1):112–120PubMedGoogle Scholar
  15. 15.
    Sare GM, Gray LJ, Bath PM (2008) Association between hormone replacement therapy and subsequent arterial and venous vascular events: a meta-analysis. Eur Heart J 29(16):2031–2041PubMedCrossRefGoogle Scholar
  16. 16.
    Squizzato A, Manfredi E, Bozzato S, Dentali F, Ageno W (2010) Antithrombotic and fibrinolytic drugs for retinal vein occlusion: a systematic review and a call for action. Thromb Haemost 103:271–276PubMedCrossRefGoogle Scholar
  17. 17.
    Karthikeyan G, Eikelboom JW, Turpie AGG, Hirsh J (2009) Does acetyl salicylic acid (ASA) have a role in the prevention of venous thromboembolism? Br J Haematol 146:142–149PubMedCrossRefGoogle Scholar
  18. 18.
    Kearon C, Kahn SR, Agnelli G et al (2008) Antithrombotic therapy for venous thromboembolic disease. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 133:454S–545SPubMedCrossRefGoogle Scholar
  19. 19.
    Ansell J, Hirsh J, Hylek E et al (2008) Pharmacology and Management of the Vitamin K Antagonists: American College of Chest Physicians Evidence-Based Clinical practice Guidelines (8th edition). Chest 133:160S–198SPubMedCrossRefGoogle Scholar
  20. 20.
    Mousa SA (2010) Oral direct factor Xa inhibitors, with special emphasis on rivaroxaban. Methods Mol Biol 663:181–201PubMedCrossRefGoogle Scholar
  21. 21.
    Connolly SJ, Ezekowitz MD, Yusuf S et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139–1151PubMedCrossRefGoogle Scholar
  22. 22.
    The Executive Steering Committee, on behalf of the ROCKET AF Study Investigators (2010) Rivaroxaban- Once daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: Rationale and Design of the ROCKET AF study. Am Heart J 159:340–347Google Scholar
  23. 23.
    Glynn RJ, Danielson E, Fonseca FAH, Genest J, Gotto AM, Kastelein JJP et al (2009) A randomized Trial of Rosuvastatin in the Prevention of Venous Thromboembolism. N Engl J Med 360:1851–1861PubMedCrossRefGoogle Scholar
  24. 24.
    Steffen LM, Folsom AR, Cushman M, Jacobs DR Jr, Rosamond WD (2007) Greater fish, fruit and vegetable intakes are related to lower incidence of venous thromboembolism: the longitudinal investigation of thromboembolism etiology. Circulation 115:188–195PubMedCrossRefGoogle Scholar
  25. 25.
    van Stralen KJ, Le Cessie S, Rosendaal FR, Doggen CJ (2007) Regular sports activities decrease the risk of venous thrombosis. J Thromb Haemost 5:2186–2192PubMedCrossRefGoogle Scholar
  26. 26.
    Di Minno MND, Russolillo A, Lupoli R, Iervolino S, Di Minno G (2011) Alcohol dosing and the heart: updating clinical evidence. Semin Thromb Hemost (in press)Google Scholar
  27. 27.
    Pomp ER, Rosendaal FR, Doggen CJ (2008) Alcohol consumption is associated with a decreased risk of venous thrombosis. Thromb Haemost 99:59–63PubMedGoogle Scholar
  28. 28.
    Ageno W, Becattini C, Brighton T et al (2008) Cardiovascular risk factors and venous thromboembolism: a meta-analysis. Circulation 117:93–102PubMedCrossRefGoogle Scholar
  29. 29.
    Di Minno G, Mannucci PM, Tufano A et al (2005) The first ambulatory screening on thromboembolism: a multicentre, cross-sectional, observational study on risk factors for venous thromboembolism. J Thromb Haemost 3:1459–1466PubMedCrossRefGoogle Scholar
  30. 30.
    Severinsen MT, Kristensen SR, Johnsen SP, Dethlefsen C, Tjonneland A, Overvad K (2009) Smoking and venous thromboembolism: a Danish follow-up study. J Thromb Haemost 7:1297–1303PubMedCrossRefGoogle Scholar
  31. 31.
    Holst AG, Jensen G, Prescott E (2010) Risk factors for venous thromboembolism. Results from the Copenhagen City Heart Study. Circulation 121:1896–1903PubMedCrossRefGoogle Scholar
  32. 32.
    Mahmoodi BK, Gansevoort RT, Veeger NJGM, Matthews AG, Navis G, Hillege HL, van der Meer J et al (2009) For the PREVEND Study Group microalbuminuria and risk of venous thromboembolism. JAMA 301:1790–1797PubMedCrossRefGoogle Scholar
  33. 33.
    Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT (2002) The metabolic syndrome and total and cardiovascular disease mortalityin middle-aged men. JAMA 288:2709–2716PubMedCrossRefGoogle Scholar
  34. 34.
    Ageno W, Prandoni P, Romualdi E et al (2006) The metabolic syndrome and the risk of venous thrombosis. A prospective, case-control study. J Thromb Haemost 4:1914–1918PubMedCrossRefGoogle Scholar
  35. 35.
    Ay C, Tengler T, Vormittag R, Simanek R, Dorda W, Vukovich T et al (2007) Venous thromboembolism—a manifestation of the metabolic syndrome. Haematologica 92(3):374–380PubMedCrossRefGoogle Scholar
  36. 36.
    Di Minno MND, Tufano A, Guida A, Di Capua M, De Gregorio AM, Cerbone AM et al (2010) Abnormally high prevalence of major components of the metabolic syndrome in subjects with early-onset idiopathic venous thromboembolism. Thrombosis Res (in press)Google Scholar
  37. 37.
    Ray JG, Lonn E, Yi Q, Rathe A, Sheridan P, Kearon C, HOPE-2 investigators et al (2007) Venous thromboembolism in association with features of the metabolic syndrome. QJM 100(11):679–684PubMedCrossRefGoogle Scholar
  38. 38.
    Steffen LM, Cushman M, Peacock JM, Heckbert SR, Jacobs DR Jr, Rosamond WD et al (2009) Metabolic syndrome and risk of venous thromboembolism: longitudinal investigation of thromboembolism etiology. J Thromb Haemost 7(5):746–751PubMedCrossRefGoogle Scholar
  39. 39.
    Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R et al (2003) Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 37(4):917–923PubMedCrossRefGoogle Scholar
  40. 40.
    Di Minno MND, Tufano A, Russolillo A, Di Minno G, Tarantino G (2010) High prevalence of nonalcoholic fatty liver in patients with idiopathic venous thromboembolism. World J Gastroenterol 16(48):6119–6122PubMedCrossRefGoogle Scholar
  41. 41.
    van der Hagen PB et al (2006) Subclinical atherosclerosis and the risk of future venous thrombosis in the Cardiovascular Health Study. J Thromb Haemost 4:1903–1908PubMedCrossRefGoogle Scholar
  42. 42.
    Reich LM et al (2006) Prospective study of subclinical atherosclerosis as a risk factor for venous thromboembolism. J Thromb Haemost 4:1909–1913PubMedCrossRefGoogle Scholar
  43. 43.
    Becattini C, Agnelli G, Prandoni P, Silingardi M, Salvi R, Taliani MR et al (2005) A prospective study on cardiovascular events after acute pulmonary embolism. Eur Heart J 26:77–83PubMedCrossRefGoogle Scholar
  44. 44.
    Bova C, Marchiori A, Noto A, Rossi V, Daniele F, Santoro C et al (2006) Incidence of arterial cardiovascular events in patients with idiopathic venous thromboembolis. A retrospective cohort study. Thromb Haemost 96:132–136PubMedGoogle Scholar
  45. 45.
    Prandoni P, Ghirarduzzi A, Prins MH et al (2006) Venous thromboembolism and the risk of subsequent symptomatic atherosclerosis. J Thromb Haemost 4:1891–1896PubMedCrossRefGoogle Scholar
  46. 46.
    Spencer FA, Ginsberg JS, Chong A, Alter DA (2008) The relationship between unprovoked venous thromboembolism, age, and acute myocardial infarction. J Thromb Haemost 6:1507–1513PubMedGoogle Scholar
  47. 47.
    Klok FA, MosInge CM, Broek L, Tamsma JT, Rosendaal FR, de Roos A, Huisman MV (2009) Risk of arterial cardiovascular events in patients after pulmonary embolism. Blood 114:1484–1488PubMedCrossRefGoogle Scholar
  48. 48.
    Schulman S, Lindmarker P, Holmstrom M, Larfars G, Carlsson A, Svensson E et al (2006) Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 months. J Thromb Haemost 4:734–742PubMedCrossRefGoogle Scholar
  49. 49.
    Young L, Ockelford P, Milne D et al (2006) Post-treatment residual thrombus increases the risk of recurrent deep vein thrombosis and mortality. Thromb Haemost 4:1919–1924CrossRefGoogle Scholar
  50. 50.
    Sørensen HT, Horvath-Puho E, Pedersen L, Baron JA, Prandoni P (2007) Venous thromboembolism and subsequent hospitalization due to acute cardiovascular events—A 20 years follow-up study. Lancet 370:1773–1779PubMedCrossRefGoogle Scholar

Copyright information

© SIMI 2011

Authors and Affiliations

  • Matteo Nicola Dario  Di Minno
    • 1
  • Antonella Tufano
    • 1
  • Walter Ageno
    • 2
  • Paolo Prandoni
    • 3
  • Giovanni Di Minno
    • 1
  1. 1.Regional Reference Centre for Coagulation Disorders“Federico II” UniversityNaplesItaly
  2. 2.Department of Clinical MedicineUniversity of InsubriaVareseItaly
  3. 3.Department of Cardiothoracic and Vascular Sciences, Thromboembolism UnitUniversity of PaduaPaduaItaly

Personalised recommendations